Hairy Cell Leukemia Clinical Trial
Official title:
A Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
The purpose of this study is to find out what effects, good and/or bad, treatment with vemurafenib (also known as Zelboraf™) has on the patient and on leukemia. Specifically, the researchers want to know how well vemurafenib eliminates leukemia from the blood.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05645744 -
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
|
||
| Active, not recruiting |
NCT03805932 -
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
|
Phase 1 | |
| Recruiting |
NCT04324112 -
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
|
Phase 2 | |
| Withdrawn |
NCT03739606 -
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT00923013 -
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
|
Phase 2 | |
| Completed |
NCT00898079 -
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
|
||
| Completed |
NCT01720758 -
Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease
|
N/A | |
| Recruiting |
NCT04815356 -
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
|
Phase 1 | |
| Recruiting |
NCT02131753 -
Therapy Optimisation for the Treatment of Hairy Cell Leukemia
|
Phase 2/Phase 3 | |
| Completed |
NCT00321555 -
LMB-2 to Treat Hairy Cell Leukemia
|
Phase 2 | |
| Completed |
NCT00586924 -
A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia
|
Phase 1 | |
| Recruiting |
NCT06340737 -
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
|
Phase 1 | |
| Recruiting |
NCT05388123 -
Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia
|
Phase 2 | |
| Not yet recruiting |
NCT05859932 -
Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients
|
||
| Recruiting |
NCT04952974 -
B-cell Chronic Lymphoid Malignancies Markers
|
||
| Recruiting |
NCT00412594 -
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
|
Phase 2 | |
| Recruiting |
NCT04775745 -
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
|
Phase 1 | |
| Completed |
NCT03010358 -
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01059786 -
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
|
Phase 2 | |
| Recruiting |
NCT04322383 -
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
|
Phase 2 |